Abstract
No public abstract is available from the verified source records.
Sana Tanweer, Sanchit Varma, Malika Adam Abeeda
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The HIV-1 capsid and reverse transcription
10.1186/s12977-021-00566-0 · 2021
The molecular architecture of the nuclear pore complex
10.1038/nature06405 · 2007
Unresolved referenced work
2002
New approaches to the treatment of chronic hepatitis B
10.3390/jcm9103187 · 2020
The process of structure-based drug design
10.1016/j.chembiol.2003.09.002 · 2003
How cryo-EM is revolutionizing structural biology
10.1016/j.tibs.2014.10.005 · 2015
Antivirals targeting the surface glycoproteins of influenza virus: mechanisms of action and resistance
10.3390/v13040624 · 2021
Unresolved referenced work
Kept as external metadata until matched
A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data
10.4155/fmc-2018-0076 · 2018
Rational drug design: one target, many paths to it
2017
Structural biology in antiviral drug discovery
10.1016/j.coph.2016.08.014 · 2016
Combating emerging viral threats
10.1126/science.aaa3778 · 2015
Unresolved referenced work
2012
10.1504/ijista.2019.10021692
10.1504/ijista.2019.10021692 · 2019
Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist
10.1128/jvi.79.20.12828-12839.2005 · 2005
Action and reaction: the arthropod-borne flaviviruses and host interferon responses
10.2217/17460794.1.4.447 · 2006
Artificial intelligence (AI) in drug design and discovery: a comprehensive review
10.1016/j.insi.2025.100049 · 2025
High-throughput crystallography for lead discovery in drug design
10.1038/nrd706 · 2002
Unresolved referenced work
1999
RCSB protein data bank: powerful new tools for exploring 3D structures
10.1093/nar/gkaa1038 · 2021
Nuclear magnetic resonance spectroscopy and imaging in animal research
10.1093/ilar.42.3.189 · 2001
Turning protein crystallisation from an art into a science
10.1016/j.sbi.2004.08.002 · 2004
Anti-SARS-CoV-2 activity of flavonoids Anti-SARS-CoV-2
2024
Unresolved referenced work
2025
QSAR modeling: where have you been? Where are you going to?
10.1021/jm4004285 · 2014
Raltegravir: the first HIV integrase inhibitor
10.1016/j.clinthera.2008.10.012 · 2008
Structural biology and drug discovery
10.1016/s1359-6446(05)03484-7 · 2005
Unresolved referenced work
2024
Prediction reliability of QSAR models: an overview of various validation tools
10.1007/s00204-022-03252-y · 2022
Viral quasispecies
10.1371/journal.pgen.1008271 · 2019
Advances and insights in the diagnosis of viral infections
10.1186/s12951-021-01081-2 · 2021
Biomolecular simulation: A computational microscope for molecular biology
10.1146/annurev-biophys-042910-155245 · 2012
Diffraction techniques in structural biology
10.1002/0471142700.nc0713s41 · 2010
Nucleosides and nucleoside analogues as emerging antiviral drugs
10.2174/1570193x17999200820163234 · 2021
Structure-based drug design; Computational strategies in drug discovery; antihypertensive agents; Antiviral drugs; molecular docking; QSAR; pharmacological insights
2026
Structural analysis of anti-retroviral drug raltegravir and its potential impurity C: investigation of solubility and stability
10.1039/d3ce01071f · 2024
Ribavirin: a clinical overview
10.1007/bf00152711 · 1986
Molecular dynamics-driven drug discovery: leaping forward with confidence
10.1016/j.drudis.2016.11.001 · 2017
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
10.1126/science.abb7498 · 2020
Unresolved referenced work
2025
Virtual screening of small molecular inhibitors against DprE1
10.3390/molecules23030524 · doi-reference
An alternative method for the evaluation of docking performance: RSR vs RMSD
10.1021/ci800084x · doi-reference
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
10.1039/d3ra06479d · doi-reference
Structural biology of SARS-CoV-2 and implications for therapeutic development
10.1038/s41579-021-00630-8 · doi-reference
HIV-1 entry and membrane fusion inhibitors
10.3390/v13050735 · doi-reference
How RIG-I like receptors activate MAVS
10.1016/j.coviro.2015.04.004 · doi-reference
Cryo-EM structure of the SARS-CoV-2 spike protein
10.1126/science.abb2507 · doi-reference
Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank
10.1111/febs.15366 · doi-reference
Integrative structural biology
10.1126/science.1228565 · doi-reference
MAVS: the next STING in cancers and other diseases
10.1016/j.critrevonc.2024.104610 · doi-reference
Elbasvir and grazoprevir for the treatment of hepatitis C
10.1080/14787210.2021.1874351 · doi-reference
Molecular docking for drug discovery and development: a widely used approach but far from perfect
10.4155/fmc-2016-0143 · doi-reference
How cryo-electron microscopy and X-ray crystallography complement each other
10.1002/pro.3022 · doi-reference
Role of the development scientist in compound lead selection and optimization
10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6 · doi-reference
Advanced technologies for protein complex production and characterization: volume II
10.1007/978-3-031-52193-5_14 · doi-reference
Development of neuraminidase inhibitors as anti-influenza virus drugs
10.1002/(sici)1098-2299(199903/04)46:3/4<176::aid-ddr4>3.0.co;2-6 · doi-reference
Overcoming antimicrobial resistance of the skin
10.1007/978-3-030-68321-4 · doi-reference
Biophysical applications in structural and molecular biology
10.1515/hsz-2021-0232 · doi-reference
Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly
10.1016/j.virusres.2019.197677 · doi-reference
Crystallography and drug design
10.1007/s12045-014-0135-6 · doi-reference
Advances in hepatitis B therapeutics
10.1177/2049936120965027 · doi-reference
Structure based drug designing approaches in SARS-CoV-2 spike inhibi-tor design
10.2174/1568026623666221103091658 · doi-reference
Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection
10.1056/nejmoa2115542 · doi-reference
Structural biology and drug discovery
10.2174/138161206777585201 · doi-reference
A beginner's guide to cryogenic electron microscopy
10.1042/bio04102046 · doi-reference
Repurposing an antiviral drug against SARS-CoV-2 main protease
10.1002/anie.202107481 · doi-reference
New roles for structure in biology and drug discovery
10.1038/80691 · doi-reference
Novel atomic-level-based ai topological descriptors: application to QSPR/QSAR modeling
10.1021/ci020362l · doi-reference
RIG-I-like receptors: their regulation and roles in RNA sensing
10.1038/s41577-020-0288-3 · doi-reference
Acute infection of viral pathogens and their innate immune escape
10.3389/fmicb.2021.672026 · doi-reference
Virus structure and structure-based antivirals
10.1016/j.coviro.2021.09.005 · doi-reference
Design and preparation of a 4:1 lamivudine–oxalic acid CAB cocrystal for improving the lamivudine purification process
10.1021/cg5005825 · doi-reference
A structural model for the retroviral proteases
10.1038/329351a0 · doi-reference
Artificial intelligence in drug discovery and development
10.1016/j.drudis.2020.10.010 · doi-reference
Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV
10.1056/nejmoa2101609 · doi-reference
Salmonella suppresses the TRIF-dependent type I interferon response in macrophages
10.1128/mbio.02051-15 · doi-reference
Computational drug discovery
10.1038/aps.2012.109 · doi-reference
Efficient inhibition of HIV using CRISPR/Cas13d nuclease system
10.3390/v13091850 · doi-reference
SCOP: A structural classification of proteins database for the investigation of sequences and structures
10.1016/s0022-2836(05)80134-2 · doi-reference
Immune response to dengue virus and prospects for a vaccine
10.1146/annurev-immunol-031210-101315 · doi-reference